TY - JOUR
T1 - Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults
T2 - Do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses?
AU - Qin, Xianhui
AU - Li, Jianping
AU - Cui, Yimin
AU - Liu, Zeyuan
AU - Zhao, Zhigang
AU - Ge, Junbo
AU - Guan, Deming
AU - Hu, Jian
AU - Wang, Yanni
AU - Zhang, Fumin
AU - Xu, Xiping
AU - Xu, Xin
AU - Wang, Xiaobin
AU - Huo, Yong
PY - 2012/6
Y1 - 2012/6
N2 - OBJECTIVES: To assess the influence of individual methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase A2756G polymorphisms on the change of serum folate concentration in response to different dosages and durations of folic acid (FA) supplementation in hypertensive Chinese adults. METHODS: A total of 480 patients with mild or moderate essential hypertension were randomly assigned to three treatment groups: (a) enalapril only (10 mg, control group); (b) enalapril FA tablet [10 : 0.4 mg (10 mg of enalapril combined with 0.4 mg of FA), low-FA group]; (c) enalapril FA tablet (10 : 0.8 mg, high-FA group), once daily for 8 weeks. Individual serum folate levels were measured at baseline, and at 4 and 8 weeks posttreatment. RESULTS: After 4 or 8 weeks of treatment, increases in serum folate were seen across all genotypes and FA dosage groups. However, compared with patients with 677CC genotype, those with CT or TT genotype in the low-FA group and TT genotype in the high-FA group still had significantly lower folate concentrations, particularly women. In the low-FA group, patients with CT or TT genotype showed an attenuated response compared with those with CC genotype (median ratio of folate at week 8 to that at baseline: CC,1.953 vs. CT,1.755 or TT,1.637, P<0.01 for both). Such an attenuated response was not observed in the high-FA group. Yet, only in the high-FA group did serum folate appear to reach a plateau after 4 weeks of treatment in all three MTHFR 677 genotypes and the methionine synthase 2756 AG/GG genotype. CONCLUSION: We demonstrated that MTHFR C677T polymorphisms can not only affect serum folate levels at the baseline and post-FA treatment, but also therapeutic responses to various dosages and durations of FA supplementation.
AB - OBJECTIVES: To assess the influence of individual methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase A2756G polymorphisms on the change of serum folate concentration in response to different dosages and durations of folic acid (FA) supplementation in hypertensive Chinese adults. METHODS: A total of 480 patients with mild or moderate essential hypertension were randomly assigned to three treatment groups: (a) enalapril only (10 mg, control group); (b) enalapril FA tablet [10 : 0.4 mg (10 mg of enalapril combined with 0.4 mg of FA), low-FA group]; (c) enalapril FA tablet (10 : 0.8 mg, high-FA group), once daily for 8 weeks. Individual serum folate levels were measured at baseline, and at 4 and 8 weeks posttreatment. RESULTS: After 4 or 8 weeks of treatment, increases in serum folate were seen across all genotypes and FA dosage groups. However, compared with patients with 677CC genotype, those with CT or TT genotype in the low-FA group and TT genotype in the high-FA group still had significantly lower folate concentrations, particularly women. In the low-FA group, patients with CT or TT genotype showed an attenuated response compared with those with CC genotype (median ratio of folate at week 8 to that at baseline: CC,1.953 vs. CT,1.755 or TT,1.637, P<0.01 for both). Such an attenuated response was not observed in the high-FA group. Yet, only in the high-FA group did serum folate appear to reach a plateau after 4 weeks of treatment in all three MTHFR 677 genotypes and the methionine synthase 2756 AG/GG genotype. CONCLUSION: We demonstrated that MTHFR C677T polymorphisms can not only affect serum folate levels at the baseline and post-FA treatment, but also therapeutic responses to various dosages and durations of FA supplementation.
KW - Folic acid supplementation
KW - Methionine synthase A2756G polymorphisms
KW - Methylenetetrahydrofolate reductase C677T polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=84861123483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861123483&partnerID=8YFLogxK
U2 - 10.1097/FPC.0b013e32834ac5e8
DO - 10.1097/FPC.0b013e32834ac5e8
M3 - Article
C2 - 21869730
AN - SCOPUS:84861123483
SN - 1744-6872
VL - 22
SP - 421
EP - 428
JO - Pharmacogenetics and Genomics
JF - Pharmacogenetics and Genomics
IS - 6
ER -